BLGTY News Alert Bio-Light Israeli (BLGTY) 4.6700 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 3:08 AM

Bio-Light Israeli (BLGTY) 4.6700 $BLGTY

BioLight Announces First IOPtiMate(TM) System Sale in Poland
PR Newswire - Mon Dec 01, 8:00AM CST
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate(TM) system to a medical center located in Poland following a successful product trial.

Merriman Capital Initiates on BioLight Life Sciences Investments Ltd. with a Buy Rating
Thomson Reuters ONE - Thu Oct 30, 8:00AM CDT
SAN FRANCISCO - October 30, 2014 - Merriman Capital, Inc. ("Merriman"

, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) with a Buy rating and a $12.00 price target.
BOLT: 21.99 (+0.01)

BioLight to Present at the Canaccord Genuity 2014 Medical Technology and Diagnostics Forum
PR Newswire - Wed Oct 22, 9:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX:BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Suzana Nahum-Zilberberg, CEO, and Itai Bar Natan, CFO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum at the Westin Grand Central in New York, NY.

BioLight to Present its IOPtiMate(TM) System at the Ophthalmology Innovation Summit @ the American Academy of Ophthalmology 2014
PR Newswire - Mon Oct 13, 8:00AM CDT
BioLight Life Sciences Investments Ltd.(TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Ronen Castro, CEO of its subsidiary IOPtima Ltd., will present at the OIS@AAO (Ophthalmology Innovation Summit @ the American Academy of Ophthalmology) on Thursday, October 16, 2014, at 10:55 a.m. at the Palmer House Hilton in Chicago, IL.
BOLT: 21.99 (+0.01)

Merriman Capital Announces Sponsorship of BioLight Life Sciences Investments Ltd. on OTCQX
Thomson Reuters ONE - Tue Sep 23, 8:00AM CDT
SAN FRANCISCO - September 23, 2014 - Merriman Capital, Inc., a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it will serve as the Principal American Liaison (PAL) for BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) ("BioLight"

as it continues trading on OTCQX(R).

BioLight Announces First IOPtiMate(TM) System Sale in Hong Kong
PR Newswire - Wed Sep 10, 7:49AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX:BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate(TM) system in Hong Kong.

BioLight Announces Issuance of U.S. Patent for the Long-Term Controlled-Release Drug-Delivery Insert Platform
PR Newswire - Wed Jul 02, 8:23AM CDT
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT) (OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces the U.S. Patent and Trademark Office has issued patent number 8,765,166 covering the device that is inserted into the eye to treat an ocular condition that contains an active agent of a free acid salt form of a prostaglandin with a low elution rate profile that is contained in the long-term controlled-release insert platform. The patent will be in effect at least until May 2031. This patent covers the technology used in Eye-D®, the company's controlled-release latanoprost insert currently in a Phase 1/2a clinical study in the U.S. for the treatment of glaucoma.
BOLT: 21.99 (+0.01)

BioLight Reports Successful Interim Results from Bladder Cancer Clinical Study
PR Newswire - Tue Jul 01, 4:23PM CDT
BioLight Life Sciences Investments Ltd. (OTC: BLGTY)(TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Micromedic Technologies (TASE: MCTC), BioLight's cancer diagnostic cluster company, achieved successful interim results in a blinded bladder cancer clinical trial with its CellDetect® technology. As a result, Micromedic will continue the trial with the goal of developing a kit for monitoring the recurrence of bladder cancer. This study is being conducted at seven medical centers and is expected to be completed in the fourth quarter of 2014.
BOLT: 21.99 (+0.01)

First Patient Enrolled in FDA Phase 1/2a Clinical Trial With BioLight's Controlled-Release Latanoprost Insert for the Treatment of Glaucoma
PR Newswire - Mon Jun 30, 8:00AM CDT
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D®, the company's controlled-release latanoprost insert for the treatment of glaucoma.
BOLT: 21.99 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Masimo's smartSET™ Revolutionizes Patient Monitoring

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Innventure Faces Major Lawsuit Over Misleading Investors

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Hyliion Class Action Deadline Nears for Investors

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Weifang's Cultural Resurgence: A Global Epigraphy Fest

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

LG OLED evo W6: UAE Roadshow Starts with a Bang

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Voter Events by Valley Community Healthcare Aim to Empower

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

AEVEX Facing Class Action Deadline Amid Stock Turmoil

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...